Temozolomide alone or combined to capecitabine for the treatment of advanced pancreatic NET.
Combining capecitabine (CAP) to temozolomide (TEM) chemotherapy in advanced pancreatic neuroendocrine tumors (PanNET) relies on limited evidences. We compared TEM-CAP to TEM alone in patients with advanced PanNET. Consecutive patients with advanced PanNET treated by TEM or TEM-CAP between 2004 and 2017 in three expert centers were included. Progression-free survival (PFS), tolerance, tumor response and overall survival were compared between the two groups. Propensity-based analyses were performed to reduce confounding bias due to the nonrandomized setting. TEM and TEM-CAP were administered in 38 patients and 100 patients, respectively, of median age 58 years. Patients in the TEM group had more functioning syndrome (p=0.03), longer median delay from diagnosis (p=0.001) and heavier pretreatment (p<0.001). Performance status was 0 in 58% vs. 65% of patients, and tumor median Ki67 index was 8% vs. 11%, respectively. Tolerance was similar, except more asthenia in the TEM group (p=0.017) and hand-foot syndrome in the TEM-CAP group (p=0.025). The ORR was 34% vs. 51% (p=0.088). Raw median PFS was similar with TEM or TEM-CAP (21.4 vs. 19.8 months, p=0.84). Although CAP tended to decrease the risk of progression at multivariate Cox analysis (HR 0.65, p=0.12), it had no effect after adjustment on the propensity score (HR 1.06, p=0.80). TEM-CAP might not prolong PFS but might achieve a higher response rate in comparison with TEM. Hence, TEM-CAP might be preferred when tumor shrinkage is the main therapeutic objective. Otherwise, TEM might be adequate in patients with impaired performance status or in case of extra-hepatic metastases.